J Korean Soc Transplant.  2016 Sep;30(3):120-124. 10.4285/jkstn.2016.30.3.120.

Chronic Rejection after Lung Transplantation

Affiliations
  • 1Division of Pulmonology, Department of Internal Medicine, Severance Hospital, Institute of Chest Diseases, Yonsei University College of Medicine, Seoul, Korea. dobie@yuhs.ac

Abstract

A new classification system for chronic rejection in lung transplantation was recently proposed. Chronic lung allograft dysfunction (CLAD) is regarded as chronic rejection after excluding other causes of allograft dysfunction. CLAD is divided into obstructive CLAD (bronchiolitis obliterans syndrome) and restrictive CLAD (restrictive allograft syndrome). In this review, we will review the latest concepts and current controversies regarding the new CLAD terminology, diagnostic approach, risk factors and possible treatment options.

Keyword

Lung transplantation; Graft rejection; Bronchiolitis obliterans

MeSH Terms

Allografts
Bronchiolitis Obliterans
Classification
Graft Rejection
Lung Transplantation*
Lung*
Risk Factors

Reference

1). Yusen RD., Edwards LB., Kucheryavaya AY., Benden C., Dipchand AI., Goldfarb SB, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report—2015;Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015. 34:1264–77.
2). Burke CM., Theodore J., Dawkins KD., Yousem SA., Blank N., Billingham ME, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest. 1984. 86:824–9.
Article
3). Yousem SA., Burke CM., Billingham ME. Pathologic pulmonary alterations in long-term human heart-lung transplantation. Hum Pathol. 1985. 16:911–23.
Article
4). Cooper JD., Billingham M., Egan T., Hertz MI., Higenbottam T., Lynch J, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 1993. 12:713–6.
5). Verleden SE., Ruttens D., Vandermeulen E., Bellon H., Van Raemdonck DE., Dupont LJ, et al. Restrictive chronic lung allograft dysfunction: Where are we now? J Heart Lung Transplant. 2015. 34:625–30.
Article
6). Sato M., Waddell TK., Wagnetz U., Roberts HC., Hwang DM., Haroon A, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant. 2011. 30:735–42.
Article
7). Verleden SE., de Jong PA., Ruttens D., Vandermeulen E., van Raemdonck DE., Verschakelen J, et al. Functional and computed tomographic evolution and survival of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant. 2014. 33:270–7.
Article
8). Verleden GM., Raghu G., Meyer KC., Glanville AR., Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014. 33:127–33.
Article
9). Kramer MR., Stoehr C., Whang JL., Berry GJ., Sibley R., Marshall SE, et al. The diagnosis of obliterative bronchiolitis after heart-lung and lung transplantation: low yield of transbronchial lung biopsy. J Heart Lung Transplant. 1993. 12:675–81.
10). Estenne M., Maurer JR., Boehler A., Egan JJ., Frost A., Hertz M, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002. 21:297–310.
Article
11). Meyer KC., Raghu G., Verleden GM., Corris PA., Aurora P., Wilson KC, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014. 44:1479–503.
Article
12). Hachem RR., Yusen RD., Meyers BF., Aloush AA., Mohanaku-mar T., Patterson GA, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant. 2010. 29:973–80.
Article
13). Snyder LD., Wang Z., Chen DF., Reinsmoen NL., Finlen-Copeland CA., Davis WA, et al. Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest. 2013. 144:226–33.
14). Ius F., Sommer W., Tudorache I., Kühn C., Avsar M., Siemeni T, et al. Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation. J Heart Lung Transplant. 2015. 34:50–8.
Article
15). Angaswamy N., Tiriveedhi V., Sarma NJ., Subramanian V., Klein C., Wellen J, et al. Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol. 2013. 74:1478–85.
Article
16). Verleden GM., Vos R., Dupont L., Van Raemdonck DE., Vanaudenaerde BM., Verleden SE. Are we near to an effective drug treatment for bronchiolitis obliterans? Expert Opin Pharmacother. 2014. 15:2117–20.
Article
17). Vos R., Vanaudenaerde BM., Verleden SE., Ruttens D., Vaneylen A., Van Raemdonck DE, et al. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation. 2012. 94:101–9.
Article
18). Verleden GM., Vanaudenaerde BM., Dupont LJ., Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006. 174:566–70.
Article
19). Neurohr C., Huppmann P., Samweber B., Leuschner S., Zimmermann G., Leuchte H, et al. Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients. J Heart Lung Transplant. 2009. 28:468–74.
Article
20). Zheng L., Whitford HM., Orsida B., Levvey BJ., Bailey M., Walters EH, et al. The dynamics and associations of airway neutrophilia post lung transplantation. Am J Transplant. 2006. 6:599–608.
Article
21). Federica M., Nadia S., Monica M., Alessandro C., Tiberio O., Francesco B, et al. Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection. Clin transplant. 2011. 25:E381–9.
Article
22). Corris PA., Ryan VA., Small T., Lordan J., Fisher AJ., Meachery G, et al. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax. 2015. 70:442–50.
Article
23). Vanaudenaerde BM., Meyts I., Vos R., Geudens N., De Wever W., Verbeken EK, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J. 2008. 32:832–43.
Article
24). Kawut SM. Lung retransplantation. Clin Chest Med. 2011. 32:367–77.
Article
25). Woodrow JP., Shlobin OA., Barnett SD., Burton N., Nathan SD. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant. 2010. 29:1159–64.
Article
26). Verleden GM., Vos R., Verleden SE., De Wever W., De Vleeschauwer SI., Willems-Widyastuti A, et al. Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation. 2011. 92:703–8.
Article
27). Todd JL., Jain R., Pavlisko EN., Finlen Copeland CA., Reynolds JM., Snyder LD, et al. Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction. Am J Respir Crit Care Med. 2014. 189:159–66.
28). Paraskeva M., McLean C., Ellis S., Bailey M., Williams T., Levvey B, et al. Acute fibrinoid organizing pneumonia after lung transplantation. Am J Respir Crit Care Med. 2013. 187:1360–8.
Article
29). Verleden SE., Ruttens D., Vandermeulen E., Vaneylen A., Dupont LJ., Van Raemdonck DE, et al. Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ? Transplantation. 2013. 95:1167–72.
30). Verleden SE., Ruttens D., Vandermeulen E., van Raemdonck DE., Vanaudenaerde BM., Verleden GM, et al. Elevated bronchoalveolar lavage eosinophilia correlates with poor outcome after lung transplantation. Transplantation. 2014. 97:83–9.
Article
31). Verleden SE., Ruttens D., Vos R., Vandermeulen E., Moelants E., Mortier A, et al. Differential cytokine, chemokine and growth factor expression in phenotypes of chronic lung allograft dysfunction. Transplantation. 2015. 99:86–93.
Article
32). Saito T., Liu M., Binnie M., Sato M., Hwang D., Azad S, et al. Distinct expression patterns of alveolar “alarmins” in subtypes of chronic lung allograft dysfunction. Am J Transplant. 2014. 14:1425–32.
Article
33). Vos R., Verleden SE., Ruttens D., Vandermeulen E., Yserbyt J., Dupont LJ, et al. Pirfenidone: a potential new therapy for restrictive allograft syndrome? Am J Transplant. 2013. 13:3035–40.
Article
34). Kohno M., Perch M., Andersen E., Carlsen J., Andersen CB., Iversen M. Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation. Transplant Proc. 2011. 43:1868–70.
Article
35). Pakhale SS., Hadjiliadis D., Howell DN., Palmer SM., Gutierrez C., Waddell TK, et al. Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation. J Heart Lung Transplant. 2005. 24:1260–8.
Article
36). Verleden SE., Todd JL., Sato M., Palmer SM., Martinu T., Pavlisko EN, et al. Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study. Am J Transplant. 2015. 15:2223–30.
Article
Full Text Links
  • JKSTN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr